Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review
- 356 Downloads
Tenofovir disoproxil fumarate (TDF)-containing regimens in the treatment of HIV-infected children have safety concerns with respect to renal and bone toxicity.
The aim of this study was to systematically review and critically appraise the literature relating to the reported renal and bone adverse effects of TDF-based regimens in the treatment of HIV-infected children from 2 to 19 years old.
Searches were performed using the Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, OvidSP, ScienceDirect and Web of Science databases and platforms. All primary studies involving tenofovir use in HIV-infected children were sought. Studies that involved the use of TDF for pre- and post-exposure prophylaxis, and treatment of chronic hepatitis B virus infection were excluded. Data on study characteristics, participant’s characteristics, therapeutic intervention and adverse effects were extracted using a piloted tool. In addition, pharmacovigilance data from the WHO Adverse Reaction database were included.
We identified 19 studies that reported the presence of renal and bone adverse effects of TDF and these included a total of 1100 study participants. The reports were in distinctly heterogeneous participant groups. A total of 287 renal and bone adverse effects were reported (250 renal and 37 bone adverse effects). Approximately 238 (21.6 %) participants were affected by these adverse effects. Of these, 15 participants stopped their TDF-containing regimen due to these adverse effects. In addition, the pharmacovigilance data from the WHO Adverse Reaction database reported 101 renal and bone adverse effects for patients whose indication was HIV/AIDS.
This systematic review summarises the reports of renal and bone adverse effects of a TDF-containing regimen in the treatment of HIV-infected children. Our findings suggest that the benefits of using TDF in children need to be balanced against the potential risk of toxicity.
KeywordsBone Mineral Density Tenofovir Electronic Supplementary Material Table Tenofovir Disoproxil Fumarate Fanconi Syndrome
The authors would like to thank Mr. Ekpereonne Esu for his timely help in literature search strategies and study selection process and Dr. Christopher Akolo for retrieval of some full-text studies.
Compliance with Ethical Standards
No sources of funding were used to assist in the preparation of this study.
Conflicts of interest
Rose Okonkwo, Anita Weidmann and Emmanuel Effa have no conflicts of interest that are directly relevant to the content of this study.
- 1.Joint United Nations Programme on HIV/AIDS. 2014 gap report. Geneva: UNAIDS; 2014. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf. Accessed 10 Mar 2015.
- 2.Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522–8.CrossRefPubMedGoogle Scholar
- 3.AIDSinfo. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Rockville: AIDSinfo; 2014. http://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0. Accessed 12 Mar 2014.
- 5.Gilead Sciences, Inc. US Food and Drug Administration approves new formulations of Viread® for use by children living with HIV. Foster City: GSI; 2012. http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1650180&highlight=. Accessed 23 Jan 2014.
- 6.World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1. Accessed 10 Jan 2014.
- 7.US Food and Drug Administration. Drugs@FDA. Viread. Maryland: US FDA; 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 19 Jan 2014.
- 8.Kearney BP, Abadi J, Rosenberg M, Nguyen M, Yale K, Flaherty J, et al. Pharmacokinetics (PK) of tenofovir DF (TDF) oral suspension in HIV-1 infected children between 2 and 8 years of age [poster]. 11th Conference on Retroviruses and Opportunistic Infections: 8–11 Feb 2004; San Francisco.Google Scholar
- 14.Gafni RJ, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118(3):e711–8.CrossRefPubMedGoogle Scholar
- 16.Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org. Accessed 21 Jan 2014.
- 17.Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York: CRD; 2009. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed 21 Jan 2014.
- 20.The Uppsala Monitoring Centre. Pharmacovigilance: WHO Programme Members. Uppsala: UMC; 2014. http://www.who-umc.org/DynPage.aspx?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442. Accessed 20 Jun 2014.
- 21.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 May 2014.
- 24.Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in human immunodeficiency virus-1 infected children with virologic suppression. Pediatr Infect Dis J. 2015;34(4):376–82. doi: 10.1097/INF.0000000000000289.CrossRefPubMedGoogle Scholar
- 25.Lim Y, Lim W, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally acquired HIV infection: a single centre cohort. In: The Family Clinic, Department of Pediatrics. Imperial College Healthcare NHS Trust. (Oral Presentation)Google Scholar
- 28.Purswani M, Patel K, Kopp JB, Seage GR 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495–500.PubMedCentralCrossRefPubMedGoogle Scholar
- 30.Costa M, Teixeira C, Costa AM, Faria MS, Mota C, Marques L. Nephrogenic diabetes insipidus associated with tenofovir administration: report of a paediatric case. Port J Nephrol Hypert. 2012;26(2):171–3.Google Scholar
- 33.Bengleil AS, Kambraki M, Al Fituri O, El Ammari I, Idris EA, Martino AM. Tenofovir toxicity in children: two clinical cases [abstract no. P214]. 9th International Congress on Drug Therapy in HIV Infection; 9–13 Nov 2008; Glasgow. http://www.hiv9.com. Accessed 23 May 2014.
- 36.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W–65.Google Scholar
- 42.Thomas V, Purdy J, Reynolds J, Hadigan C, Hazra R. Bone mineral density in adolescents infected with HIV perinatally or childhood: data from the NIH intramural program [abstract]. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8–11 Feb 2009; Montreal.Google Scholar
- 43.Jacobson D, Dimeglio L, Hazra R, et al. Clinical determinants of bone mineral density in perinatally HIV-infected children [abstract]. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8–11 Feb 2009; Montreal.Google Scholar
- 50.Rosso R, Parodi A, Torrisi C, De Terlizzi F, Viscoli C, Vignolo M. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience. AIDS Res Hum Retroviruses. 2010;26(12):1265–6.CrossRefPubMedGoogle Scholar
- 54.Stagi S, Bindi G, Galluzzi F, Galli L, Salti R, de Martino M. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. Clin Endocrinol. 2004;61(692):699.Google Scholar